Skip to main page content

Review

. 2019 Apr 11;380(15):1450-1462.

doi: 10.1056/NEJMra1713263.

Hepatocellular Carcinoma

Augusto Villanueva¹

Affiliations

Affiliation

¹ From the Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Graduate School of Biomedical Sciences, and the Division of Hematology and Medical Oncology, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York.

PMID: 30970190
DOI: 10.1056/NEJMra1713263

Review

Hepatocellular Carcinoma

Augusto Villanueva. N Engl J Med. 2019.

. 2019 Apr 11;380(15):1450-1462.

doi: 10.1056/NEJMra1713263.

Author

Augusto Villanueva¹

Affiliation

¹ From the Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Graduate School of Biomedical Sciences, and the Division of Hematology and Medical Oncology, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York.

PMID: 30970190
DOI: 10.1056/NEJMra1713263

No abstract available

PubMed Disclaimer

Comment in

Hepatocellular Carcinoma.
Kim YS, Shin SW. Kim YS, et al. N Engl J Med. 2019 Jul 4;381(1):e2. doi: 10.1056/NEJMc1906565. N Engl J Med. 2019. PMID: 31269385 No abstract available.
Hepatocellular Carcinoma.
Duran SR, Jaquiss RDB. Duran SR, et al. N Engl J Med. 2019 Jul 4;381(1):e2. doi: 10.1056/NEJMc1906565. N Engl J Med. 2019. PMID: 31269386 No abstract available.

Similar articles

[Diagnosis and treatment of hepatocellular carcinoma].
Spangenberg HC, Zuber-Jerger I, Mohr L, Thimme R, Blum HE. Spangenberg HC, et al. Dtsch Med Wochenschr. 2004 Feb 20;129(8):368-72. doi: 10.1055/s-2004-819893. Dtsch Med Wochenschr. 2004. PMID: 14961445 Review. German. No abstract available.
Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma.
Italian Association for the Study of the Liver (AISF); AISF Expert Panel; AISF Coordinating Committee; Bolondi L, Cillo U, Colombo M, Craxì A, Farinati F, Giannini EG, Golfieri R, Levrero M, Pinna AD, Piscaglia F, Raimondo G, Trevisani F, Bruno R, Caraceni P, Ciancio A, Coco B, Fraquelli M, Rendina M, Squadrito G, Toniutto P. Italian Association for the Study of the Liver (AISF), et al. Dig Liver Dis. 2013 Sep;45(9):712-23. doi: 10.1016/j.dld.2013.01.012. Epub 2013 Feb 23. Dig Liver Dis. 2013. PMID: 23769756
From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world.
Dimitroulis D, Damaskos C, Valsami S, Davakis S, Garmpis N, Spartalis E, Athanasiou A, Moris D, Sakellariou S, Kykalos S, Tsourouflis G, Garmpi A, Delladetsima I, Kontzoglou K, Kouraklis G. Dimitroulis D, et al. World J Gastroenterol. 2017 Aug 7;23(29):5282-5294. doi: 10.3748/wjg.v23.i29.5282. World J Gastroenterol. 2017. PMID: 28839428 Free PMC article. Review.
Managing localized unresectable hepatocellular carcinoma.
Narang-Master J, Rizzolo D. Narang-Master J, et al. JAAPA. 2015 Jan;28(1):27-34. doi: 10.1097/01.JAA.0000458854.46279.d8. JAAPA. 2015. PMID: 25486501 Review.
Octreotide for unresectable hepatocellular carcinoma: beyond the first sight.
Samonakis DN, Christodoulakis N, Kouroumalis EA. Samonakis DN, et al. J Clin Gastroenterol. 2006 Jan;40(1):86-7. doi: 10.1097/01.mcg.0000190778.50279.26. J Clin Gastroenterol. 2006. PMID: 16340641 No abstract available.

See all similar articles

Cited by

A novel liver-function-indicators-based prognosis signature for patients with hepatocellular carcinoma treated with anti-programmed cell death-1 therapy.
Zheng Z, Mei J, Guan R, Zhang J, Xiong X, Gan J, Li S, Guo R. Zheng Z, et al. Cancer Immunol Immunother. 2024 Jun 4;73(8):158. doi: 10.1007/s00262-024-03713-6. Cancer Immunol Immunother. 2024. PMID: 38834790 Free PMC article.
STEAP2 promotes hepatocellular carcinoma progression via increased copper levels and stress-activated MAP kinase activity.
Torrez CZ, Easley A, Bouamar H, Zheng G, Gu X, Yang J, Chiu YC, Chen Y, Halff GA, Cigarroa FG, Sun LZ. Torrez CZ, et al. Sci Rep. 2024 Jun 3;14(1):12753. doi: 10.1038/s41598-024-63368-2. Sci Rep. 2024. PMID: 38830975 Free PMC article.
CircMYBL2 facilitates hepatocellular carcinoma progression by regulating E2F1 expression.
Yi J, Li B, Yin X, Liu L, Song C, Zhao Y, Cai M, Tang H, Chen D, Lyu N. Yi J, et al. Oncol Res. 2024 May 23;32(6):1129-1139. doi: 10.32604/or.2024.047524. eCollection 2024. Oncol Res. 2024. PMID: 38827325 Free PMC article.
Novel immune classification based on machine learning of pathological images predicts early recurrence of hepatocellular carcinoma.
Tan T, Hu H, Zhang W, Cui J, Lu Z, Li X, Song J. Tan T, et al. Front Oncol. 2024 May 17;14:1391486. doi: 10.3389/fonc.2024.1391486. eCollection 2024. Front Oncol. 2024. PMID: 38826785 Free PMC article.
Quantifying the natural growth rate of hepatocellular carcinoma: A real-world retrospective study in southwestern China.
Tu L, Xie H, Li Q, Lei PG, Zhao PL, Yang F, Gong C, Yao YL, Zhou S. Tu L, et al. World J Hepatol. 2024 May 27;16(5):800-808. doi: 10.4254/wjh.v16.i5.800. World J Hepatol. 2024. PMID: 38818290 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- The Lens - Patent Citations
Medical
- MedlinePlus Health Information